In this Issue:
Rituximab after ASCT in mantle cell lymphoma
Additional cytogenetic abnormalities at childhood CML diagnosis
CAR-T cells: durable molecular remissions in CLL after ibrutinib failure
ATO consolidation allows anthracycline dose reduction in paediatric APL
Guadecitabine in treatment-naive AML
Copanlisib in R/R indolent or aggressive lymphoma
FLT3-ITD/DNMT3A double mutation predicts poor prognosis in AML after chemo or alloHSCT
FDG-PET–driven consolidation in DLBCL
Lenalidomide maintenance after first-line therapy for high-risk CLL
Second primary malignancies and mortality in imatinib-treated CML
Please login below to download this issue (PDF)